IT1208
IT1208 is a humanized anti-CD4 monoclonal IgG1 antibody. IT1208 depletes CD4+ T cells with a manageable safety profile in vivo. IT1208 can be used for colon cancer research.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human
CD4
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human B cell lymphoma Raji cells (1 × 106, i.p.) induced-mice prior to Healthy human peripheral blood mononuclear cells (PBMCs) (20 × 106, i.p.)[2]
-
Dosage:200 μg
-
Administration:i.p., twice a week for 4 weeks
-
Result:Effectively prevented the development of xenogeneic GVHD in mice in experiments using cells from 3 donors.
Exerted only a partial preventive effect on xenogeneic GVHD in mice in the experiment using cells from 1 single donor.
Significantly prevented GVHD-associated damage to target tissues including the skin, salivary glands, liver and lung in mice.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Shitara K, et al., Matsushima K, Doi T. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. J Immunother Cancer. 2019 Jul 24;7(1):195. [Content Brief]
[2]. Liu M, Yang J, Xu B, Zhang X. Tumor metastasis: Mechanistic insights and therapeutic interventions. MedComm (2020). 2021 Dec 2;2(4):587-617. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)